<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="45924">Trimethoprim</z:chebi>-<z:chebi fb="0" ids="9328">sulfadiazine</z:chebi> (<z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-SDZ) (Tribressin tablets 120 - 100 mg <z:chebi fb="0" ids="9328">sulfadiazine</z:chebi>, 20-mg <z:chebi fb="0" ids="45924">trimethoprim</z:chebi> [Coopers Animal Health, Inc., A Pitman-Moore Company, Mundelein, Ill.]) is a broad spectrum antibiotic combination effective in the treatment of <z:mp ids='MP_0001794'>bacterial</z:mp> <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, <z:hpo ids='HP_0000010'>urinary tract infections</z:hpo>, <z:hpo ids='HP_0000999'>pyoderma</z:hpo>, <z:hpo ids='HP_0001287'>meningitis</z:hpo>, and <z:hpo ids='HP_0000024'>prostatitis</z:hpo>.(1) In clinical trials in puppies and adult dogs, <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-SDZ was considered safe at both the manufacturer's recommended dose (15 mg/kg, b.i.d., or 30 mg/kg, u.i.d., per os for &lt; 14 days(2)) and at 10 times that dose for 20 dayS.(3) Many <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, however, require prolonged high-dose therapy for resolution </plain></SENT>
<SENT sid="1" pm="."><plain>The following study describes two cases of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and <z:hpo ids='HP_0100806'>sepsis</z:hpo> associated with intermittent, <z:hpo ids='HP_0011010'>chronic</z:hpo> (17-25 days), high-dose (25-30 mg/kg, b.i.d., per os) <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-SDZ therapy recommended for the treatment of <z:hpo ids='HP_0000999'>pyoderma</z:hpo>.(4-7) </plain></SENT>
</text></document>